H Luecking1, T Engelhorn2, S Lang2, P Goelitz2, S Kloska2, K Roessler3, A Doerfler2. 1. From the Departments of Neuroradiology (H.L., T.E., S.L., P.G., S.K., A.D.) hannes.luecking@uk-erlangen.de. 2. From the Departments of Neuroradiology (H.L., T.E., S.L., P.G., S.K., A.D.). 3. Neurosurgery (K.R.), University of Erlangen-Nuremberg, Erlangen, Germany.
Abstract
BACKGROUND AND PURPOSE: Endovascular flow diverters are increasingly used for the treatment of cerebral aneurysms. We assessed the safety and efficacy of the Flow-Redirection Endoluminal Device (FRED) in a consecutive series of 50 patients. MATERIALS AND METHODS: Inclusion criteria were wide-neck, blister-like, or fusiform/dissecting aneurysms independent of size, treated with the FRED between February 2014 and May 2015. Assessment criteria were aneurysm occlusion, manifest ischemic stroke, bleeding, or death. The occlusion rate was assessed at 3 months with flat panel CT and at 6 months with DSA by using the Raymond classification and the O'Kelly-Marotta grading scale. RESULTS: Fifty patients with 52 aneurysms were treated with 54 FREDs; 20 patients were treated with the FRED and coils. Aneurysm size ranged from 2.0 to 18.5 mm. Deployment of the FRED was successful in all cases. There were no device-associated complications. One patient developed mild stroke symptoms that fully receded within days. There have been no late-term complications so far and no treatment-related mortality. Initial follow-up at 3 months showed complete occlusion in 72.3% of the overall study group, Six-month follow-up showed total and remnant-neck occlusion in 87.2% of patients, distributed over 81.5% of the FRED-only cases and 95.0% of the cases with combined treatment. CONCLUSIONS: The FRED flow diverter is a safe device for the treatment of cerebral aneurysms of various types. Our data reveal high occlusion rates at 3 and 6 months, comparable with those in other flow diverters. Long-term occlusion rates are expected.
BACKGROUND AND PURPOSE: Endovascular flow diverters are increasingly used for the treatment of cerebral aneurysms. We assessed the safety and efficacy of the Flow-Redirection Endoluminal Device (FRED) in a consecutive series of 50 patients. MATERIALS AND METHODS: Inclusion criteria were wide-neck, blister-like, or fusiform/dissecting aneurysms independent of size, treated with the FRED between February 2014 and May 2015. Assessment criteria were aneurysm occlusion, manifest ischemic stroke, bleeding, or death. The occlusion rate was assessed at 3 months with flat panel CT and at 6 months with DSA by using the Raymond classification and the O'Kelly-Marotta grading scale. RESULTS: Fifty patients with 52 aneurysms were treated with 54 FREDs; 20 patients were treated with the FRED and coils. Aneurysm size ranged from 2.0 to 18.5 mm. Deployment of the FRED was successful in all cases. There were no device-associated complications. One patient developed mild stroke symptoms that fully receded within days. There have been no late-term complications so far and no treatment-related mortality. Initial follow-up at 3 months showed complete occlusion in 72.3% of the overall study group, Six-month follow-up showed total and remnant-neck occlusion in 87.2% of patients, distributed over 81.5% of the FRED-only cases and 95.0% of the cases with combined treatment. CONCLUSIONS: The FRED flow diverter is a safe device for the treatment of cerebral aneurysms of various types. Our data reveal high occlusion rates at 3 and 6 months, comparable with those in other flow diverters. Long-term occlusion rates are expected.
Authors: A H Y Chiu; A K Cheung; J D Wenderoth; L De Villiers; H Rice; C C Phatouros; T P Singh; T J Phillips; W McAuliffe Journal: AJNR Am J Neuroradiol Date: 2015-05-21 Impact factor: 3.825
Authors: Tibor Becske; David F Kallmes; Isil Saatci; Cameron G McDougall; István Szikora; Giuseppe Lanzino; Christopher J Moran; Henry H Woo; Demetrius K Lopes; Aaron L Berez; Daniel J Cher; Adnan H Siddiqui; Elad I Levy; Felipe C Albuquerque; David J Fiorella; Zsolt Berentei; Miklós Marosfoi; Saruhan H Cekirge; Peter K Nelson Journal: Radiology Date: 2013-02-15 Impact factor: 11.105
Authors: Mario Zanaty; Nohra Chalouhi; Stavropoula I Tjoumakaris; Robert H Rosenwasser; L Fernando Gonzalez; Pascal Jabbour Journal: Front Neurol Date: 2014-02-28 Impact factor: 4.003
Authors: H Oishi; T Fujii; M Suzuki; N Takano; K Teranishi; K Yatomi; T Kitamura; M Yamamoto; S Aoki; H Arai Journal: AJNR Am J Neuroradiol Date: 2019-05-02 Impact factor: 3.825
Authors: Hannes Luecking; Arnd Doerfler; Philipp Goelitz; Philip Hoelter; Tobias Engelhorn; Stefan Lang Journal: Interv Neuroradiol Date: 2019-10-09 Impact factor: 1.610
Authors: M A Möhlenbruch; O Kizilkilic; M Killer-Oberpfalzer; F Baltacioglu; C Islak; M Bendszus; S Cekirge; I Saatci; N Kocer Journal: AJNR Am J Neuroradiol Date: 2017-08-10 Impact factor: 3.825
Authors: Hannes Luecking; Tobias Struffert; Philipp Goelitz; Tobias Engelhorn; Sebastian Brandner; Joji B Kuramatsu; Stefan Lang; Manuel Schmidt; Arnd Doerfler Journal: Clin Neuroradiol Date: 2020-05-08 Impact factor: 3.649
Authors: José M Pumar; Antonio Mosqueira; Jorge Olier; Claudio Rodriguez-Fernandez; Pedro Vega; Eva Gonzalez-Diaz Journal: Front Neurol Date: 2021-07-09 Impact factor: 4.003